Table 1.
Most commonly prescribed antimicrobials or antimicrobial combinations for 5724 cats diagnosed with sporadic cystitis, recurrent cystitis and pyelonephritis
| Sporadic cystitis (n = 5051) | Recurrent cystitis (n = 182) | Pyelonephritis (n = 491) | Overall (n = 5724) |
|---|---|---|---|
| Cefovecin* (n = 3056 [61%]) | Cefovecin* (n = 110 [60%]) | Cefovecin* (n = 132 [27%]) | Cefovecin* (n = 3298 [58%]) |
| Amoxicillin–clavulanic acid † (n = 1076 [21%]) | Amoxicillin–clavulanic acid † (n = 25 [14%]) | Amoxicillin–clavulanic acid † (n = 90 [18%]) | Amoxicillin–clavulanic acid † (n = 1191 [21%]) |
| Orbifloxacin* (n = 203 [4.0%]) | Marbofloxacin* (n = 14 [7.7%]) | Marbofloxacin* (n = 82 [17%]) | Marbofloxacin* (n = 285 [5.0%]) |
| Marbofloxacin* (n = 189 [3.7%]) | Orbifloxacin* (n = 13 [7.1%]) | Orbifloxacin* (n = 32 [6.5%]) | Orbifloxacin* (n = 248 [4.3%]) |
| Amoxicillin ‡ (n = 164 [3.2%])Cefovecin* + amoxicillin–clavulanic acid † (n = 123 [2.4%]) | Amoxicillin ‡ (n = 8 [4.4%])Enrofloxacin* (n = 4 [2.2%]) | Amoxicillin–clavulanic acid † + marbofloxacin* (n = 22 [4.5%]) | Amoxicillin ‡ (n = 183 [3.2%])Cefovecin* + amoxicillin–clavulanic acid † (n = 130 [2.3%]) |
| Enrofloxacin* (n = 21 [4.3%]) | |||
| Enrofloxacin* (n = 44 [0.9%])Cefovecin* + marbofloxacin* (n = 28 [0.6%]) | Cefovecin* + amoxicillin–clavulanic acid † (n = 2 [1.1%]) | Pradofloxacin* (n = 18 [3.7%])Cefovecin* + marbofloxacin* (n = 16 [3.3%]) | Enrofloxacin* (n = 69 [1.2%])Cefovecin* + marbofloxacin* (n = 45 [0.8%]) |
| Pradofloxacin* (n = 2 [1.1%]) |
*
World Health Organization (WHO) antimicrobial classification: highest priority critically important
†
WHO antimicrobial classification: critically important
‡
WHO antimicrobial classification: highly important